GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Metropolis Healthcare Ltd (BOM:542650) » Definitions » Debt-to-EBITDA

Metropolis Healthcare (BOM:542650) Debt-to-EBITDA : 0.00 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Metropolis Healthcare Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Metropolis Healthcare's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Metropolis Healthcare's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Metropolis Healthcare's annualized EBITDA for the quarter that ended in Dec. 2024 was ₹2,983 Mil. Metropolis Healthcare's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Metropolis Healthcare's Debt-to-EBITDA or its related term are showing as below:

BOM:542650' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0   Med: 0.31   Max: 1.01
Current: 0.57

During the past 9 years, the highest Debt-to-EBITDA Ratio of Metropolis Healthcare was 1.01. The lowest was 0.00. And the median was 0.31.

BOM:542650's Debt-to-EBITDA is ranked better than
75.7% of 107 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.61 vs BOM:542650: 0.57

Metropolis Healthcare Debt-to-EBITDA Historical Data

The historical data trend for Metropolis Healthcare's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metropolis Healthcare Debt-to-EBITDA Chart

Metropolis Healthcare Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only 0.31 0.38 1.01 0.88 0.68

Metropolis Healthcare Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.60 - 0.51 -

Competitive Comparison of Metropolis Healthcare's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Metropolis Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Metropolis Healthcare's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Metropolis Healthcare's Debt-to-EBITDA falls into.



Metropolis Healthcare Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Metropolis Healthcare's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(779.967 + 1190.678) / 2916.925
=0.68

Metropolis Healthcare's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 2982.592
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Metropolis Healthcare  (BOM:542650) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Metropolis Healthcare Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Metropolis Healthcare's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Metropolis Healthcare Business Description

Traded in Other Exchanges
Address
Dr. Annie Besant Road, 4th Floor, East Wing, Plot-254 B, Nirlon House, Worli, Mumbai, MH, IND, 400 030
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.

Metropolis Healthcare Headlines

No Headlines